Pfizer Reports P-III Study Results of Antibiotic Aztreonam-Avibactam for Serious Bacterial Infections
- The P-III program consists (REVISIT) study evaluating ATM-AVI ± MTZ vs MER ± COL and (ASSEMBLE) study of ATM-AVI in 422 & 15 patients with serious bacterial inf. due to gram-bacteria across 81 & 12 locations in 20 & 9 countries
- In cIAI & HAP/VAP patients, the cure rate in the ITT analysis set was (76.4% vs 74.0%) & (45.9% vs 41.7%) with a treatment difference of 2.4% & 4.3% in (REVISIT) study; cure rate (85.1% vs 79.5% & 46.7% vs 54.5%) in the CE analysis set; all-cause 28-day mortality rates (1.9% & 10.8% vs 2.9% vs 19.4%), respectively, the incidence of SAEs (19.3% vs 18.2%) & no patient experienced a treatment-related SAE
- The results from both studies are expected to form the basis for planned regulatory filings in the EU, UK, China & the US in H2’23. Pfizer holds the rights globally to commercialize ATM-AVI outside of the US & Canada
Ref: Pfizer | Image: Pfizer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.